{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:01:13Z","timestamp":1771380073503,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,17]]},"DOI":"10.7759\/cureus.103794","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T01:07:21Z","timestamp":1771376841000},"source":"Crossref","is-referenced-by-count":0,"title":["Corticosteroid Taper Duration and Relapse Rate in Immune Checkpoint Inhibitor-Induced Pneumonitis: A Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Rodrigo","family":"Furlan Silva Fabri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anvitha","family":"Soundararajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo Myronn","family":"De Melo Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007056","article-title":"Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study","volume":"11","author":"Karayama M","year":"2023","unstructured":"Karayama M, Inui N, Inoue Y, et al.. Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study. J Immunother Cancer. 2023, 11:10.1136\/jitc-2023-007056","journal-title":"J Immunother Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-024-03284-3","article-title":"Risk factors for relapse of immune-related pneumonitis after 6-week oral prednisolone therapy: a follow-up analysis of a phase II study","volume":"24","author":"Karayama M","year":"2024","unstructured":"Karayama M, Inui N, Inoue Y, et al.. Risk factors for relapse of immune-related pneumonitis after 6-week oral prednisolone therapy: a follow-up analysis of a phase II study. BMC Pulm Med. 2024, 24:495. 10.1186\/s12890-024-03284-3","journal-title":"BMC Pulm Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2024.06.009","article-title":"Impact of durvalumab on the duration and complexity of corticosteroid therapy for pneumonitis after chemoradiotherapy","volume":"25","author":"Murata S","year":"2024","unstructured":"Murata S, Horinouchi H, Morishita M, et al.. Impact of durvalumab on the duration and complexity of corticosteroid therapy for pneumonitis after chemoradiotherapy. Clin Lung Cancer. 2024, 25:369-78. 10.1016\/j.cllc.2024.06.009","journal-title":"Clin Lung Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.resmer.2022.100969","article-title":"Prevalence and outcome of steroid-resistant\/refractory pneumonitis induced by immune checkpoint inhibitors","volume":"82","author":"Camard M","year":"2022","unstructured":"Camard M, Besse B, Cariou PL, et al.. Prevalence and outcome of steroid-resistant\/refractory pneumonitis induced by immune checkpoint inhibitors. Respir Med Res. 2022, 82:100969. 10.1016\/j.resmer.2022.100969","journal-title":"Respir Med Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000840","article-title":"Chronic immune checkpoint inhibitor pneumonitis","volume":"8","author":"Naidoo J","year":"2020","unstructured":"Naidoo J, Cottrell TR, Lipson EJ, et al.. Chronic immune checkpoint inhibitor pneumonitis. J Immunother Cancer. 2020, 8:10.1136\/jitc-2020-000840","journal-title":"J Immunother Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials","volume":"42","author":"Verheijden RJ","year":"2024","unstructured":"Verheijden RJ, de Groot JS, Fabriek BO, Hew MN, May AM, Suijkerbuijk KP. Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials. J Clin Oncol. 2024, 42:3713-24. 10.1200\/JCO.24.00191","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006982","article-title":"Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis","volume":"11","author":"Li Y","year":"2023","unstructured":"Li Y, Jia X, Zhang Y, et al.. Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis. J Immunother Cancer. 2023, 11:10.1136\/jitc-2023-006982","journal-title":"J Immunother Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001731","article-title":"Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes","volume":"9","author":"Balaji A","year":"2021","unstructured":"Balaji A, Hsu M, Lin CT, et al.. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes. J Immunother Cancer. 2021, 9:10.1136\/jitc-2020-001731","journal-title":"J Immunother Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000575","article-title":"Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis","volume":"4","author":"Park C","year":"2019","unstructured":"Park C, Keam B, Yoon SH, et al.. Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis. ESMO Open. 2019, 4:e000575. 10.1136\/esmoopen-2019-000575","journal-title":"ESMO Open"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae147","article-title":"Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis","volume":"29","author":"Moodabagil M","year":"2024","unstructured":"Moodabagil M, Easterling R, Peng J, et al.. Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis. Oncologist. 2024, 29:e1575-85. 10.1093\/oncolo\/oyae147","journal-title":"Oncologist"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, Version 1.2019","volume":"17","author":"Thompson JA","year":"2019","unstructured":"Thompson JA, Schneider BJ, Brahmer J, et al.. Management of immunotherapy-related toxicities, Version 1.2019. J Natl Compr Canc Netw. 2019, 17:255-89. 10.6004\/jnccn.2019.0013","journal-title":"J Natl Compr Canc Netw"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-168","article-title":"Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer","volume":"11","author":"Tao H","year":"2022","unstructured":"Tao H, Li F, Wu D, et al.. Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer. Transl Lung Cancer Res. 2022, 11:381-92. 10.21037\/tlcr-22-168","journal-title":"Transl Lung Cancer Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/449389-corticosteroid-taper-duration-and-relapse-rate-in-immune-checkpoint-inhibitor-induced-pneumonitis-a-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T01:07:22Z","timestamp":1771376842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/449389-corticosteroid-taper-duration-and-relapse-rate-in-immune-checkpoint-inhibitor-induced-pneumonitis-a-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.103794","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,17]]}}}